US4117118A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Organic compounds
Assignee: Sandoz AG
•
Filing: 1977-03-28
•
Granted: 1978-09-26
•
Expires: 1997-03-28
Abstract
Abstract This invention provides new antibiotics produced by cultivating a strain of the fungus species, Cylindrocarpon lucidum Booth or Tolypocladium inflatum Gams in contact with a nutrient medium, the antibiotics being useful anti-inflammatory and immunosuppressive agents.
Inventors
- 👤 Eugen Harri
- 👤 Artur Ruegger
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-24 11:51
CPC Classifications
C; C07; C07K; C07K7/00; C07K7/64; C07K7/645; A; A61; A61K; A61K38/00; Y; Y10; Y10S; Y10S930/00; Y10S930/01; Y10S930/19; Y10S930/28
Claims Analysis
Total Claims: 19
Claim 1
Independent Claim
257 words
Antibiotic S7481/F-1 having the following characteristics, when an amorphous form: U.v. spectrum [CH 3 OH; c = 1.063 g/1; d = 0.01 cm] as shown in FIG. 1 of the accompanying drawings, I.r. spectrum [CH 2 Cl 2 ] as shown in FIG. 2 of the accompanying drawings, Proton N.M.R. spectrum [90 MHz; CDCL 3 ] as shown in FIG. 3 of the accompanying drawings, High resolution mass spectrum [ion acceleration 4kv; temperature ion source 290° C; pressure 5.10 -6 mm Hg] peak of mass = m/e 1183.831 [± 0.004] corresponding to C 62 H 109 N 11 O 11 recognisable as product of elimination of water from C 62 H 111 N 11 O 12 ; and empirical formula C 62 H 111 N 11 O 12 ; or antibiotic S7481/F-2 having the following characteristics, when in amorphous form: U.v. spectrum [CH 3 OH; c = 1.062 g/l; d = 0.01 cm] as shown in FIG. 4 of the accompanying drawings; I.r. spectrum [CH 2 Cl 2 ] as hown in FIG. 5 of the accompanying drawings; Proton N.M.R. spectrum [90 MHz; CDCl 3 ] as shown in FIG. 6 of the accompanying drawings; High resolution mass spectrum [ion acceleration 4 kv; ion source temperature 290° C; pressure 5.10 -6 mm Hg] peak of mass m/e 1169.815 (± 0.006) corresponding to C 61 H 107 N 11 O 11 , the product of water elimination from C 61 H 109 N 11 O 12 ; empirical formula C 61 H 109 N 11 O 12 .
Claim 2
Dependent Claim
257 words
Antibiotic S7481/F-1 having the following characteristics, when an amorphous form: U.v. spectrum [CH 3 OH; c = 1.063 g/1; d = 0.01 cm] as shown in FIG. 1 of the accompanying drawings, I.r. spectrum [CH 2 Cl 2 ] as shown in FIG. 2 of the accompanying drawings, Proton N.M.R. spectrum [90 MHz; CDCL 3 ] as shown in FIG. 3 of the accompanying drawings, High resolution mass spectrum [ion acceleration 4kv; temperature ion source 290° C; pressure 5.10 -6 mm Hg] peak of mass = m/e 1183.831 [± 0.004] corresponding to C 62 H 109 N 11 O 11 recognisable as product of elimination of water from C 62 H 111 N 11 O 12 ; and empirical formula C 62 H 111 N 11 O 12 ; or antibiotic S7481/F-2 having the following characteristics, when in amorphous form: U.v. spectrum [CH 3 OH; c = 1.062 g/l; d = 0.01 cm] as shown in FIG. 4 of the accompanying drawings; I.r. spectrum [CH 2 Cl 2 ] as hown in FIG. 5 of the accompanying drawings; Proton N.M.R. spectrum [90 MHz; CDCl 3 ] as shown in FIG. 6 of the accompanying drawings; High resolution mass spectrum [ion acceleration 4 kv; ion source temperature 290° C; pressure 5.10 -6 mm Hg] peak of mass m/e 1169.815 (± 0.006) corresponding to C 61 H 107 N 11 O 11 , the product of water elimination from C 61 H 109 N 11 O 12 ; empirical formula C 61 H 109 N 11 O 12 .
Claim 3
Dependent Claim
4 words
S7481/F-1 of structure ##STR3##
Claim 4
Dependent Claim
4 words
S7481/F-1 of structure ##STR3##
Claim 5
Dependent Claim
7 words
S7481/F-1 of claim 2 in amorphous form.
Claim 6
Dependent Claim
7 words
S7481/F-1 of claim 2 in solid form.
Claim 7
Dependent Claim
4 words
S7481/F-2 of structure ##STR4##
Claim 8
Dependent Claim
4 words
S7481/F-2 of structure ##STR4##
Claim 9
Dependent Claim
22 words
A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 in association with a pharmaceutical carrier or diluent.
Claim 10
Dependent Claim
28 words
A method of treating arthritis in animals, which comprises administering to an animal in need of such treatment a therapeutically effective amount of a compound of claim 1.
Claim 11
Dependent Claim
38 words
A method of suppressing the formation of lymphocytes and immunocytes in animals in need of immunosuppressive treatment, which comprises administering to an animal in need of such treatment a therapeutically effective amount of a compound of claim 1.
Claim 12
Dependent Claim
29 words
A method of treating auto-immune diseases in animals, which comprises administering to an animal in need of such treatment a therapeutically effective amount of a compound of claim 1.
Claim 13
Dependent Claim
31 words
A method of suppressing the rejection of transplants in animals, which comprises administering to an animal in need of such treatment a therapeutically effective amount of a compound of claim 1.
Claim 14
Dependent Claim
12 words
A method of claim 10, wherein the transplant is a skin transplant.
Claim 15
Dependent Claim
28 words
A method of treating arthritis in animals, which comprises administering to an animal in need of such treatment a therapeutically effective amount of a compound of claim 2.
Claim 16
Dependent Claim
38 words
A method of suppressing the formation of lymphocytes and immunocytes in animals in need of immunosuppressive treatment, which comprises administering to an animal in need of such treatment a therapeutically effective amount of a compound of claim 2.
Claim 17
Dependent Claim
29 words
A method of treating atuo-immune diseases in animals, which comprises administering to an animal in need of such treatment a therapeutically effective amount of a compound of claim 2.
Claim 18
Dependent Claim
31 words
A method of suppressing the rejection of transplants in animals, which comprises administering to an animal in need of such treatment a therapeutically effective amount of a compound of claim 2.
Claim 19
Dependent Claim
12 words
A method of claim 15, wherein the transplant is a skin transplant.
References Cited (Backward Citations)
DE2455859A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1981-09-25 | 1982-03-27 | 1982-09-26 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1985-09-25 | 1986-03-27 | 1986-09-26 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1989-09-25 | 1990-03-27 | 1990-09-26 | $7700.00 | Window Closed / Lapsed |